Drug intelligence / Profile preview

177Lu-PSMA-597

Development stage: Unknown
Lead developer: Novartis
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-PSMA-597 is a therapeutic radiopharmaceutical consisting of the beta-emitting radioisotope lutetium-177 conjugated to the novel PSMA-targeting peptide PSMA-597. It is designed to treat metastatic castration-resistant prostate cancer (mCRPC) by binding to prostate-specific membrane antigen (PSMA) expressed on the surface of prostate cancer cells. Once bound, the agent is internalized, and the lutetium-177 delivers targeted ionizing radiation, causing DNA damage and cell death in the tumor cells while sparing surrounding healthy tissue. It is currently being evaluated in the Phase II OPTIMAL-PSMA trial to optimize dosing regimens and receptor intensification.

Other names: Lutetium (177Lu) PSMA-597

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 177Lu-PSMA-597.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-PSMA-597.

Explore the full profile